CUSIP No. 29668H708


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
(Rule 13d-102)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )1
 
 
ESSA Pharma Inc.
(Name of Issuer)
 
 
Common Shares, no par value
(Title of Class of Securities)
 
29668H708
(CUSIP Number)
 
 
July 31, 2020
(Date of Event Which Requires Filing of this Statement)



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)    

1.The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.


1



CUSIP No. 29668H708


1.
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

Pfizer Inc.

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
                 (a) [ ]
                 (b) [ ]
3.
SEC USE ONLY

4.
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.
SOLE VOTING POWER 1,675,000
6.
SHARED VOTING POWER -0-
7.
SOLE DISPOSITIVE POWER 1,675,000
8.
SHARED DISPOSITIVE POWER -0-
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,675,000*

10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
                         [ ]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.0% *
12.
TYPE OF REPORTING PERSON CO

* Based on 27,924,339 Common Shares outstanding upon the closing of the Issuer’s registered public offering of 7,100,000 Common Shares on July 31, 2020 (without giving effect to any exercise of the underwriters’ option to purchase additional Common Shares), as reported in the Issuer’s Preliminary Prospectus Supplement dated July 27, 2020 and filed with the Securities and Exchange Commission on July 28, 2020.

2



CUSIP No. 29668H708

SCHEDULE 13G

ITEM 1(a)
NAME OF ISSUER:
 
 
 
ESSA Pharma Inc.
 
 
ITEM 1(b)
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
 
 
 
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5
 
 
ITEM 2(a)
NAME OF PERSON FILING:
 
 
 
Pfizer Inc.
 
 
ITEM 2(b)
ADDRESS OF PRINCIPAL BUSINESS OFFICE:
 
 
 
235 East 42nd Street, New York, NY 10017
 
 
ITEM 2(c)
CITIZENSHIP:
 
 
 
Delaware
 
 
ITEM 2(d)
TITLE OF CLASS OF SECURITIES:
 
 
 
Common Shares, no par value
 
 
ITEM 2(e)
CUSIP NUMBER:
 
 
 
29668H708
 
 
ITEM 3
STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):
 
 
 
Not applicable.

3



CUSIP No. 29668H708


ITEM 4
OWNERSHIP:
 
 
 
 
The information requested in this item is incorporated herein by reference to the cover page to this Schedule 13G.
 
 
 
 
ITEM 5
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
 
 
 
Not applicable.
 
 
ITEM 6
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
 
 
 
Not applicable.
 
 
ITEM 7
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
 
 
 
Not applicable.

ITEM 8
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
 
 
 
Not applicable.
 
 
ITEM 9
NOTICE OF DISSOLUTION OF GROUP:
 
 
 
Not applicable.
 
 
 
 
ITEM 10
CERTIFICATION:
 
 
 
By signing below the undersigned certifies that, to the best of the undersigned’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.



4



CUSIP No. 29668H708


SIGNATURE

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 6, 2020

 
PFIZER INC.

 
By:
/s/ Susan Grant
 
Name:
Susan Grant
 
Title:
Assistant Secretary
 
 
 


5